Evaxion A (EVAX) Total Non-Current Liabilities (2021 - 2025)
Evaxion A's (EVAX) quarterly Total Non-Current Liabilities came in at $7.1 million in Q4 2025, down 27.2% YoY from $9.8 million in Q4 2024, and down 34.76% on a QoQ basis from $10.9 million in Q2 2025.
Evaxion A (EVAX) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends
Evaxion A (EVAX) has 5 years of Total Non-Current Liabilities data on file, last reported at $7.1 million in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 27.2% year-over-year to $7.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.1 million (down 27.2% YoY) and the FY2025 annual result came in at $7.1 million, down 27.2% from the prior year.
- Total Non-Current Liabilities fell to $7.1 million in Q4 2025, from $10.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $10.9 million in Q2 2025 to a low of $1.0 million in Q2 2021.
- A 5-year average of $7.5 million and a median of $9.8 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 819.77% — and 2025, when it declined 27.2%.
- Tracing EVAX's Total Non-Current Liabilities over 5 years: stood at $3.4 million in 2021, then jumped by 192.68% to $10.0 million in 2022, then increased by 5.76% to $10.5 million in 2023, then slipped by 7.26% to $9.8 million in 2024, then retreated by 27.2% to $7.1 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $7.1 million (Q4 2025), $10.9 million (Q2 2025), and $9.8 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.50 Bn | 131.65 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.10 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.59 Bn | 60.41 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 56.75 Bn | 51.62 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.80 Bn | 9.41 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 9.32 Bn |
| 10 | Evaxion A | 28.11 Mn | 28.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.11 Mn |
| Jun 30, 2025 | 10.90 Mn |
| Dec 31, 2024 | 9.77 Mn |
| Jun 30, 2024 | 10.16 Mn |
| Dec 31, 2023 | 10.53 Mn |
| Jun 30, 2023 | 10.17 Mn |
| Dec 31, 2022 | 9.96 Mn |
| Jun 30, 2022 | 9.45 Mn |
| Mar 31, 2022 | 10.01 Mn |
| Dec 31, 2021 | 3.40 Mn |
| Sep 30, 2021 | 3.54 Mn |
| Jun 30, 2021 | 1.03 Mn |
| Mar 31, 2021 | 1.11 Mn |